Overview

Astragaloside IV is a triterpenoid saponin and one of the principal bioactive compounds found in the root of Astragalus membranaceus, a plant with a long history of use in traditional Chinese medicine. It has attracted considerable scientific interest due to preclinical evidence suggesting it can activate telomerase, the enzyme responsible for maintaining telomere length, which has implications for cellular aging and longevity research.

Beyond its telomerase-related activity, astragaloside IV has been studied for cardioprotective effects, including attenuation of myocardial ischemia-reperfusion injury and reduction of cardiac fibrosis in animal models. The compound appears to exert anti-inflammatory action through modulation of the NF-κB signaling pathway and suppression of pro-inflammatory cytokine production. Additional preclinical studies have explored its neuroprotective, hepatoprotective, and immunomodulatory potential.

Astragaloside IV has limited oral bioavailability due to its large molecular weight and poor intestinal absorption, which has prompted research into enhanced delivery formulations. While it is commercially available as a dietary supplement, human clinical data remain limited, and most evidence derives from in vitro and animal studies. The compound is structurally related to cycloastragenol, its aglycone metabolite, which is also marketed for its purported anti-aging effects.

Mechanism of Action

Cycloartane Triterpenoid Saponin

Astragaloside IV (AS-IV) is the principal bioactive saponin isolated from Astragalus membranaceus root. It is a cycloartane-type triterpene glycoside with a tetracyclic scaffold that enables interactions with multiple cellular targets involved in inflammation, oxidative stress, and tissue repair (PMID: 24614112).

Telomerase Activation

AS-IV has been identified as a telomerase activator, enhancing the catalytic activity of human telomerase reverse transcriptase (hTERT) by upregulating hTERT gene expression through MAPK/ERK signaling. This promotes telomere maintenance in immune cells and fibroblasts, potentially counteracting replicative senescence. This mechanism underpins the patented telomerase activator TA-65, derived from astragalus (PMID: 22035048).

NF-kB & Inflammatory Pathway Modulation

AS-IV suppresses NF-kB activation through inhibition of IKKbeta phosphorylation and IkB-alpha degradation, reducing transcription of TNF-alpha, IL-1beta, IL-6, COX-2, and iNOS. It also inhibits TLR4/MyD88/TRAF6 upstream signaling in macrophages, blunting the innate immune inflammatory cascade triggered by LPS and damage-associated molecular patterns (PMID: 27720823).

PI3K/Akt/mTOR & Cardioprotection

AS-IV activates the PI3K/Akt survival pathway, phosphorylating GSK-3beta and Bad to inhibit mitochondrial apoptosis. In cardiomyocytes, this preserves mitochondrial membrane potential, reduces caspase-3/9 activation, and decreases infarct size in ischemia-reperfusion models. AS-IV also enhances VEGF expression and promotes angiogenesis in ischemic tissue (PMID: 26231173).

Nrf2-Mediated Antioxidant Defense

AS-IV activates the Keap1-Nrf2-ARE pathway, upregulating HO-1, SOD, glutathione peroxidase, and NQO1. This reduces ROS accumulation and lipid peroxidation, contributing to renal, hepatic, and neuronal protection in oxidative stress models (PMID: 28214597).

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Generally well-tolerated at standard doses (10-50 mg daily), with mild gastrointestinal symptoms such as nausea, bloating, or stomach discomfort being the most frequently reported complaints
• Occasional headache and dizziness have been noted in clinical trial participants
• Mild fatigue or drowsiness reported in some users, particularly during initial supplementation

Serious Adverse Effects

• Limited long-term human safety data exists, as most clinical studies have been short-duration (8-16 weeks)
• Theoretical immunostimulatory effects could be problematic in autoimmune conditions, though direct evidence is sparse
• No significant organ toxicity has been reported in available human or animal studies at recommended doses

Contraindications

• Individuals with autoimmune disorders (lupus, rheumatoid arthritis, multiple sclerosis) should use with caution due to potential immune-stimulating properties inherited from the parent astragalus plant
• Not recommended for individuals who have undergone organ transplantation or are on immunosuppressive therapy
• Should be discontinued at least two weeks prior to scheduled surgery due to potential effects on immune function and wound healing

Drug Interactions

• May interact with immunosuppressive drugs (cyclosporine, tacrolimus, azathioprine, corticosteroids) by counteracting their effects through immune activation
• Potential interaction with anticoagulant and antiplatelet medications, as some astragalus compounds have demonstrated mild antithrombotic activity
• May enhance the effects of antiviral medications; concurrent use should be monitored by a healthcare provider
• Theoretical interaction with lithium due to potential diuretic effects altering lithium clearance
• May potentiate the effects of hypoglycemic agents, requiring blood sugar monitoring in diabetic patients

Special Populations

• Insufficient safety data for use during pregnancy and breastfeeding; avoidance is recommended
• Pediatric dosing has not been established in clinical trials
• Elderly patients with compromised immune regulation should consult a healthcare provider before use

Pharmacokinetic Profile